Ownership and insider activity for Sagimet Biosciences Inc. (SGMT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Price
| Price | $10.46 |
| Market Cap | $341M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.2M | $68.7M | $56.7M | $158000 | $75.1M | $75.8M | $35.0M |
| Short-term Investments | 0 | 0 | 0 | $32.2M | $19.8M | $75.4M | $78.1M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $10.8M | $68.7M | $58.7M | $32.8M | $96.6M | $152.8M | $116.4M |
| Property, Plant & Equipment | $318000 | $194000 | $342000 | $212000 | $73000 | $77000 | $78000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $11.2M | $69.0M | $59.0M | $33.0M | $96.7M | $160.3M | $116.5M |
| Accounts Payable | $1.2M | $513000 | $761000 | $1.1M | $186000 | $1.4M | $1.3M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $2.1M | $1.9M | $2.4M | $5.3M | $5.7M | $4.5M | $5.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $136.5M | $204.9M | $217.3M | $220.0M | $5.7M | $4.5M | $5.1M |
| Retained Earnings | -$155.6M | -$166.9M | -$191.4M | -$221.9M | -$249.7M | -$295.3M | -$346.3M |
| Total Equity | -$125.3M | -$135.9M | -$158.3M | -$186.9M | $91.1M | $155.8M | $111.4M |
| Total Debt | $341000 | $210000 | $348000 | $211000 | $65000 | $78000 | $78000 |
| Net Debt | -$9.9M | -$68.5M | -$56.4M | -$32.1M | -$94.8M | -$151.2M | -$113.0M |
| Working Capital | $8.7M | $66.8M | $56.2M | $27.5M | $91.0M | $148.3M | $111.3M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 45.02 |
Profitability
| Return on Equity | -31.96% |
| Return on Invested Capital | -20.39% |
| Return on Assets | -17.87% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACHV · ARCT · ASMB · AVIR · FHTX · HUMA · IMRX
Explore sector: Healthcare · Biotechnology
More sections of SGMT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks